Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic engineering could salvage once-promising anti-cancer agents

11.06.2002


A group of anti-cancer agents that once produced dismal results in clinical trials could once again be a promising tool in fighting the deadly disease, thanks to research by a team of chemists at the University of Washington and in Germany.



The agents, called maytansinoids, were first discovered in the 1970s when scientists looked for tumor inhibitors in a rare Ethiopian plant. The same group of maytansinoids was later isolated from a new bacteria species. The compounds held great promise because of their exceptional potency, and early tests indicated they were effective against some tumors and leukemia lines.

But the compounds were difficult to come by in quantities large enough to manufacture drugs and, when potential treatments were developed, they proved too strong when tested in clinical trials.


"These compounds were too potent. They were toxic to patients," said Tin-Wein Yu, a UW research assistant professor of chemistry. "We thought if we could modify the chemical structure to make the agents more appropriate for cancer patients, that would be beneficial. And we could use the same strategy to ease the side effects."

UW researchers headed by Heinz Floss, an emeritus chemistry professor, teamed with researchers from Rheinische Wilhems-Universität in Bonn, Germany, to develop ways of modifying genes that create maytansinoids and then produce cancer treatments that are more effective against tumors and better tolerated by patients.

Their efforts essentially relied on using the modified genes to produce the anti-cancer agent. The first step was to locate the genes that control maytansinoid formation and clone them. They first gained access to genes that control maytansinoid production, then altered the maytansinoid structure at the genetic level.

"If you can manipulate the production genes, it makes the process much easier," said Yu, who is the lead author of a paper describing the work in the June 11 issue of the Proceedings of the National Academies of Science.

To clone the genes, the researchers snipped the genome of the bacteria (Actinosynnema pretiosum) into small bits to create a genomic library. They used a gene that already had been cloned from another microorganism (Amycolatopsis mediterranei) as a reference to screen the library and find the genes needed for maytansinoid construction. Having access to the genes that control the formation of maytansinoids allows scientists to manipulate the structure of the anti-cancer agent at the DNA level.

The work, for which the UW has applied for a patent, allows for a detailed analysis of maytansinoid formation at both the genetic and biochemical levels. It also sets the stage to modify maytansinoids through genetic engineering, so they are less toxic to humans, are more effective against cancer and bond easily with delivery agents.

Several companies are in discussions about the possibility of using the research to combine maytansinoids with antibodies that target tumors. The antibodies would search out specific cancer antigens attach only to cancer cells, Yu said. The maytansinoids then can enter the cancer cells and destroy them without damaging surrounding healthy tissue.

"It is a warhead strategy," he said.

The work has provided researchers with a number of options other than simply deciphering the biosynthesis of pre-existing compounds, Yu said. Manipulating the structure, he said, ultimately could lead to development of more effective cancer drugs.



The research was funded by grants from the National Institutes of Health, Deutsche Forschungsgemeinschaft (Germany’s central public funding organization for academic research), the Fonds der Chemischen Industrie in Germany and the North Atlantic Treaty Organization.

For more information, contact Yu at (206) 543-3791 or yu@u.washington.edu

Vince Stricherz | EurekAlert

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>